Related Experiment Video
Updated: Jun 18, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
The echinocandins: three useful choices or three too many?
1Department of Medical Microbiology, Crosshouse Hospital, NHS Ayrshire and Arran, Kilmarnock KA2 0BE, UK. abhijit.bal@nhs.net
Abstract:
Echinocandins act by inhibiting 1,3-beta-D-glucan synthesis in the fungal cell wall. The three licensed agents in this class, namely anidulafungin, caspofungin and micafungin, have a favourable pharmacological profile. These agents are narrow spectrum with clinically relevant activity against Candida and Aspergillus spp. Several trials have established the non-inferiority of these agents over existing agents in the treatment of invasive fungal infections. Caspofungin is also licensed for empirical antifungal therapy of presumed fungal infections in patients with febrile neutropenia. This paper reviews the literature on echinocandins.
Related Concept Videos
Antifungal Agents
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Anthelminthic Agents
Antibiotic Selection
